Aura Biosciences (AURA) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $6.10, -3.79% vs the prior close of $6.34.
- Volume 762.44K shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
AURA slides 3.8% to $6.10. Closed at $6.10, -3.79% vs the prior close of $6.34. Day range $6.09–$6.35, opened at $6.31.
AURA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — AURA slides 3.8% to $6.10
- Closed at $6.10, -3.79% vs the prior close of $6.34. Day range $6.09–$6.35, opened at $6.31.
- Volume was 762.44K shares, 0.8x its 50-day average of 921.12K.
- Price is -12.6% vs its 50-day average ($6.98) and -8.4% vs its 200-day average ($6.66).
- 52-week range $4.73–$9.53; today's close sits at 29% of that range, 36.0% below the 52-week high.
Oct 15, 2026 — AURA rises 2.8% to $6.34
- Closed at $6.34, +2.76% vs the prior close of $6.17. Day range $6.17–$6.41, opened at $6.23.
- Volume was 604.50K shares, 0.7x its 50-day average of 915.33K.
- Price is -9.6% vs its 50-day average ($7.01) and -4.8% vs its 200-day average ($6.66).
- 52-week range $4.73–$9.53; today's close sits at 34% of that range, 33.5% below the 52-week high.
Oct 14, 2026 — AURA dips 1.6% to $6.17, 3 down days in a row
- Closed at $6.17, -1.59% vs the prior close of $6.27. Day range $6.09–$6.28, opened at $6.21.
- Volume was 1.01M shares, 1.1x its 50-day average of 900.68K.
- Price is -12.2% vs its 50-day average ($7.03) and -7.3% vs its 200-day average ($6.65).
- 52-week range $4.73–$9.53; today's close sits at 30% of that range, 35.3% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — AURA slides 4.1% to $6.27 on 1.9x normal volume
- Closed at $6.27, -4.13% vs the prior close of $6.54. Day range $6.18–$6.56, opened at $6.53.
- Volume was 1.66M shares, 1.9x its 50-day average of 875.86K — unusually heavy trading.
- Price is -11.0% vs its 50-day average ($7.05) and -5.7% vs its 200-day average ($6.65).
- 52-week range $4.73–$9.53; today's close sits at 32% of that range, 34.2% below the 52-week high.
Oct 12, 2026 — AURA ends flat (+0.0%) to $6.54
- Closed at $6.54, +0.00% vs the prior close of $6.54. Day range $6.50–$6.70, opened at $6.55.
- Volume was 613.10K shares, 0.7x its 50-day average of 869.48K.
- Price is -7.4% vs its 50-day average ($7.06) and -1.6% vs its 200-day average ($6.65).
- 52-week range $4.73–$9.53; today's close sits at 38% of that range, 31.4% below the 52-week high.
Oct 9, 2026 — AURA rises 0.5% to $6.54, 3 up days in a row
- Closed at $6.54, +0.54% vs the prior close of $6.51. Day range $6.46–$6.70, opened at $6.48.
- Volume was 962.60K shares, 1.1x its 50-day average of 856.09K.
- Price is -7.5% vs its 50-day average ($7.07) and -1.6% vs its 200-day average ($6.65).
- 52-week range $4.73–$9.53; today's close sits at 38% of that range, 31.4% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — AURA rises 0.7% to $6.51 on 2.0x normal volume
- Closed at $6.51, +0.70% vs the prior close of $6.46. Day range $6.36–$6.61, opened at $6.41.
- Volume was 1.69M shares, 2.0x its 50-day average of 831.87K — unusually heavy trading.
- Price is -8.1% vs its 50-day average ($7.08) and -2.1% vs its 200-day average ($6.64).
- 52-week range $4.73–$9.53; today's close sits at 37% of that range, 31.8% below the 52-week high.
Oct 7, 2026 — AURA jumps 4.7% to $6.46
- Closed at $6.46, +4.70% vs the prior close of $6.17. Day range $6.10–$6.56, opened at $6.10.
- Volume was 723.70K shares, 0.9x its 50-day average of 826.18K.
- Price is -8.9% vs its 50-day average ($7.09) and -2.7% vs its 200-day average ($6.64).
- 52-week range $4.73–$9.53; today's close sits at 36% of that range, 32.2% below the 52-week high.
Oct 6, 2026 — AURA dips 0.8% to $6.17
- Closed at $6.17, -0.80% vs the prior close of $6.22. Day range $6.10–$6.27, opened at $6.26.
- Volume was 607.50K shares, 0.7x its 50-day average of 819.07K.
- Price is -13.1% vs its 50-day average ($7.10) and -7.0% vs its 200-day average ($6.64).
- 52-week range $4.73–$9.53; today's close sits at 30% of that range, 35.3% below the 52-week high.
Oct 5, 2026 — AURA rises 2.1% to $6.22
- Closed at $6.22, +2.13% vs the prior close of $6.09. Day range $6.05–$6.42, opened at $6.09.
- Volume was 589.80K shares, 0.7x its 50-day average of 813.79K.
- Price is -12.7% vs its 50-day average ($7.12) and -6.3% vs its 200-day average ($6.64).
- 52-week range $4.73–$9.53; today's close sits at 31% of that range, 34.8% below the 52-week high.
Oct 2, 2026 — AURA rises 0.8% to $6.09 on 2.7x normal volume
- Closed at $6.09, +0.83% vs the prior close of $6.04. Day range $5.97–$6.15, opened at $6.11.
- Volume was 2.10M shares, 2.7x its 50-day average of 776.43K — unusually heavy trading.
- Price is -14.7% vs its 50-day average ($7.14) and -8.2% vs its 200-day average ($6.64).
- 52-week range $4.73–$9.53; today's close sits at 28% of that range, 36.1% below the 52-week high.
AURA latest news & SEC filings
Every SEC filing by or about AURA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 1, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 1, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 20, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 12, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$45.64M (prior year -$27.02M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.48 (prior year -$0.47) (loss widened vs Jun 30, 2025)
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 2.05 — Costs tied to exiting activities / restructuring.
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 8.01 — Reported other events the company considers important.
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade AURA
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 11, 2026, May 4, 2026, Mar 30, 2026. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.22% (largest 6.7%).
- Liquidity: about 931.43K shares (≈$5.68M) trade per day on average.
- 52-week position: $6.10 vs a range of $4.73–$9.53 (29% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Anthony S Gibney sold 12,824 shares on Jun 16, 2026.
- Latest filings: 10-Q Aug 11, 2026; 8-K Aug 11, 2026; 8-K Aug 5, 2026.
- Share count: 103.70M shares outstanding (Aug 6, 2026), +66.9% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
AURA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 6.31 | 6.35 | 6.09 | 6.10 | 762.44K |
| Oct 15, 2026 | 6.23 | 6.41 | 6.17 | 6.34 | 604.50K |
| Oct 14, 2026 | 6.21 | 6.28 | 6.09 | 6.17 | 1.01M |
| Oct 13, 2026 | 6.53 | 6.56 | 6.18 | 6.27 | 1.66M |
| Oct 12, 2026 | 6.55 | 6.70 | 6.50 | 6.54 | 613.10K |
| Oct 9, 2026 | 6.48 | 6.70 | 6.46 | 6.54 | 962.60K |
| Oct 8, 2026 | 6.41 | 6.61 | 6.36 | 6.51 | 1.69M |
| Oct 7, 2026 | 6.10 | 6.56 | 6.10 | 6.46 | 723.70K |
| Oct 6, 2026 | 6.26 | 6.27 | 6.10 | 6.17 | 607.50K |
| Oct 5, 2026 | 6.09 | 6.42 | 6.05 | 6.22 | 589.80K |
| Oct 2, 2026 | 6.11 | 6.15 | 5.97 | 6.09 | 2.10M |
| Oct 1, 2026 | 6.36 | 6.36 | 6.00 | 6.04 | 807.30K |
| Sep 30, 2026 | 6.21 | 6.36 | 6.12 | 6.28 | 677.50K |
| Sep 29, 2026 | 6.13 | 6.18 | 6.04 | 6.15 | 795.00K |
| Sep 28, 2026 | 6.03 | 6.17 | 6.00 | 6.15 | 483.60K |
| Sep 25, 2026 | 6.18 | 6.18 | 5.99 | 6.00 | 1.12M |
| Sep 24, 2026 | 6.01 | 6.25 | 5.95 | 6.15 | 963.10K |
| Sep 23, 2026 | 6.42 | 6.47 | 5.98 | 6.02 | 1.04M |
| Sep 22, 2026 | 6.32 | 6.46 | 6.27 | 6.45 | 601.60K |
| Sep 21, 2026 | 6.52 | 6.54 | 6.25 | 6.36 | 819.10K |
About Aura Biosciences
Aura Biosciences (AURA) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in BOSTON, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1501796.
AURA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jeremy Bender | Director | Jul 8, 2026 |
| Teresa Marie Bitetti | Director | Jun 15, 2026 |
| Natalie C. Holles | See Remarks | May 19, 2026 |
| David Michael Johnson | Director | Jun 15, 2026 |
| Antony C. Mattessich | Director | Jun 15, 2026 |
| Sapna Srivastava | Director | Jun 15, 2026 |
| Los Pinos Elisabet De | See Remarks | Mar 3, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Susan Abu-Absi | Chief Operating Officer | Sep 1, 2026 |
| Amy Elazzouzi | SVP, Finance & PAO | Sep 1, 2026 |
| Anthony S Gibney | See Remarks | Jun 16, 2026 |
| Natalie C. Holles | See Remarks | May 19, 2026 |
| Janet Jill Hopkins | Chief Medical Officer | Sep 1, 2026 |
| Conor Kilroy | See Remarks | Jul 1, 2026 |
| Erica Kratz | Chief Reg. & Quality Officer | Sep 1, 2026 |
| Julie Person | Chief People Officer | Sep 1, 2026 |
| Mark Plavsic | Chief Technology Officer | Mar 3, 2026 |
| Los Pinos Elisabet De | See Remarks | Mar 3, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 16, 2026 | Anthony S Gibney | Sale | 12,824 | $6.42 |
| Jun 16, 2026 | Anthony S Gibney | Sale | 12,824 | $6.42 |
| Jun 16, 2026 | Anthony S Gibney | Sale | 12,824 | $6.42 |
| Jun 16, 2026 | Anthony S Gibney | Sale | 12,824 | $6.42 |
| May 7, 2026 | Capital Management Company, Lp Matrix | Sale | 6,922,870 | $5.64 |
| May 7, 2026 | Capital Management Company, Lp Matrix | Sale | 6,922,870 | $5.64 |
| May 7, 2026 | David E. Goel | Sale | 6,922,870 | $5.64 |
| May 7, 2026 | David E. Goel | Sale | 6,922,870 | $5.64 |
| May 7, 2026 | Capital Management Company, Lp Matrix | Sale | 6,922,870 | $5.64 |
| May 7, 2026 | Capital Management Company, Lp Matrix | Sale | 6,922,870 | $5.64 |
| May 7, 2026 | David E. Goel | Sale | 6,922,870 | $5.64 |
| May 7, 2026 | David E. Goel | Sale | 6,922,870 | $5.64 |
| Apr 16, 2026 | Conor Kilroy | Sale | 11,738 | $7.02 |
| Apr 16, 2026 | Conor Kilroy | Sale | 11,738 | $7.02 |
| Apr 16, 2026 | Conor Kilroy | Sale | 11,738 | $7.02 |
AURA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-106.19M | -1.76 | $-84.74M |
| Dec 31, 2024 | — | $-86.92M | -1.75 | $-79.81M |
| Dec 31, 2023 | — | $-76.41M | -1.93 | $-63.85M |
| Dec 31, 2022 | — | $-58.76M | -1.96 | $-54.60M |
| Dec 31, 2021 | — | $-35.25M | -8.95 | $-32.41M |
Latest balance sheet: total assets $348.13M, total liabilities $32.86M, cash $67.84M (as of Jun 30, 2026).
AURA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $8.04 |
| May 11, 2026 | 8-K Item 2.02 (results) | $8.19 |
| May 4, 2026 | 8-K Item 2.02 (results) | $8.35 |
| Mar 30, 2026 | 8-K Item 2.02 (results) | $6.20 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $5.53 |
| Aug 13, 2025 | 8-K Item 2.02 (results) | $7.23 |
| May 15, 2025 | 8-K Item 2.02 (results) | $5.18 |
| Mar 24, 2025 | 8-K Item 2.02 (results) | $7.00 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $10.65 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Mar 27, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on AURA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.